Regulatory Momentum Dova's lead product Doptelet is FDA approved since 2018 with a second indication added in 2019 and EU approval in 2019, signaling a mature regulatory footing to support commercial discussions. This creates sales opportunities with hepatology and interventional procedures where platelet counts impact outcomes, and suggests potential for cross border sales in Europe through established channels.

Strategic Sobi Collaboration As a wholly owned subsidiary of Sobi with an announced merger in 2019, Dova can leverage Sobi's European distribution and commercial reach to accelerate Doptelet adoption in EU markets, enabling joint business development and shared sales resources.

Commercial Leadership The appointment of a chief commercial officer in 2018 indicates a dedicated go to market strategy. With a mid sized team in a rare disease space, there is room to scale in the United States and Europe through partner channels or contract sales organizations to reach hematology and hepatology specialists and high value centers.

Rare Disease Focus Dova emphasizes a high value portfolio for patients with rare diseases, which aligns with payer consolidation and niche KOL engagement. This presents opportunities to build payer strategies, patient advocacy partnerships, and key opinion leader driven studies to support uptake.

Global Expansion EU approval alongside US presence provides a foundation for global access strategies. Engage hospital group purchasing, specialty distributors, and payer negotiations to accelerate Doptelet adoption in hepatology, surgery and oncology supportive care and explore additional indications.